MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
UNITY Biotechnology, Inc.(NASDAQ: UBX)*
Organization & Developments: Unity Biotechnology
Parents
UNITY Biotechnology, Inc.(NASDAQ: UBX)*
Children
*Candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089
*Focus on clearing senescent cells, and creating senolytic medicines leaving normal cells unaffected.
*Focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases.
*The company's products in development include UBX0101, targeting knee osteoarthritis, and UBX1967, a preclinical product targeting ophthalmologic diseases.
*Therapeutics that prevent, halt, and reverse various diseases of aging.
*Unity Biotechnology is a biotechnology company that develops drugs which target senescent cells.
2020: A Look Inside Unity Bio's Transition To An Ophthalmology Company
2021: Our First Take On Unity Biotechnology
2022: Unity Biotechnology: Share Consolidation On The Back Of Positive Trial Results_seekingalpha.com
2023: Unity once again lays off large number of staff, narrows focus to ophthalmology assets
Jumps
Finance & Acquisitions: Unity Biotechnology
Key People: Unity Biotechnology